Objective: This study aimed to determine local control and overall survival of patients with medically inoperable early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.Methods: A total of 35 patients [6 (17%) females and 29 (83%) males] with medically inoperable early-stage non-small cell lung cancer and who were treated with stereotactic ablative body radiotherapy by a CyberKnife robotic radiotherapy machine between 2009 and 2015 were evaluated retrospectively.Results: The median age of patients was 69 (55–83) years. The ECOG performance score of 24 (67%) and 11 (33%) patients were 1 and 2, respectively. Tumor was staged as cT1 in 19 (54%) patients and cT2 in 16 (46%) patients. Tumor was centrally located in 6 (17%) patients and peripheral in 29 (83%) patients. The mean planning target volume (PTV) was 124.1 mm³ (14.5–233.7 mm³). As regards the tumor-tracking system, X-Sight lung tracking system was used in 31 (88%) patients, gold fiducials in 3 (9%) patients, and X-Sight spine tracking system in 1 (3%) patient. 43 Gy (30-60 Gy) radiotherapy has been described to 81% isodose line (70-92%) and delivered in 3 and 5 fractions to 33 (94%), and 2 (6%) patients respectively.Conclusion: During 21 months median follow-up time (2–51 months) local recurrence was observed in only 2 (5%) patients. The 2-year local control rate was 93.4%, the 2-year overall survival rate was 45%, and the mean survival time was 21.4 months. Grade 3 toxicity was observed in only two patients; no grade 4–5 toxicity was observed. The effect of age, performance status, T stage, PTV volume, and radiation dose over local control and overall survival were investigated, but no significant correlation was found. A high local control rate with no major toxicity was obtained by stereotactic ablative body radiotherapy in the patients with medically inoperable early-stage non-small cell lung cancer
1. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395–409.
2. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer. 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):278–313.
3. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II nonsmall cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax 2001;56:628–38.
4. Solda F, Lodge M, Ashley S. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; Sytematic review and comparison with a surgical cohort. Radiother Oncol 2015;109:1–7.
5. Potters L, Kavanagh B, Galvin JM. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010;76:326– 32.
6. Wulf J, Hädinger U, Oppitz U. Stereotactic radiotherapy of extracranial targets: CT-simulation and accuracy of treatment in the stereotactic body frame. Radiother Oncol 2000;57:225–36.
7. Guckenberger M, Klement RJ, Allgauer M. Applicability of the linear quadratic formalism for modeling local tumor control probability in high dose perfraction stereotactic body radiotherapy for early stagenon-small cell lung cancer. Radiother Oncol 2013;109:13–20.
8. Navarria P, Ascolese AM, Mancosu P. Volumetric modulatedarctherapywithflatteningfilterfree (FFF) beamsforstereotactic body radiationtherapy (SBRT) in patients with medically inoperable early stage nonsmall cell lung cancer (NSCLC). Radiother Oncol 2013;107:414–8.
9. Amini, A, Yeh, N, Gaspar, L.E. Stereotactic body radiationtherapy (sbrt) for lung cancer patients previously treated with conventional radiotherapy: A review. Radiat Oncol 2014;9:210.
10. Jones GC, Kehrer JD, Kahn J, Koneru BN, Narayan R, Thomas TO, et al. Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients. Clin Lung Cancer 2015;16:413– 30.
11. Zhang B, Zhu F, Ma X. Matched-paircomparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: A systematic review and meta-analysis. Radiother Oncol 2014;112:250–5.